Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

Berufsverband der Augenärzte Deutschlands e.V. (BVA); Deutsche Ophthalmologische Gesellschaft (DOG); Retinologische Gesellschaft e.V. (RG)

doi:10.1055/a-0731-8952

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2018; 235(10): 1165-1177
DOI: 10.1055/a-0731-8952

Leitlinien, Stellungnahmen und Empfehlungen

Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss^[*]

Therapeutische Strategien, Stand 24.04.2018 Berufsverband der Augenärzte Deutschlands e.V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft e.V. (RG)

Abstract

Full Text

References

Literatur

Verwendete Literatur
1 Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. Ophthalmologe 2010; 107: 583-596
2 Ehlers JP, Kim SJ, Yeh S. et al. Therapies for macular edema associated with branch retinal vein occlusion: a report by the American academy of ophthalmology. Ophthalmology 2017; 124: 1412-1423
3 Berger AR, Cruess AF, Altomare F. et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 2015; 234: 6-25
4 Pulido JS, Flaxel CJ, Adelman RA. et al. Retinal vein occlusions preferred practice pattern(^®) guidelines. Ophthalmology 2016; 123: P182-P208
5 Pielen A, Feltgen N, Isserstedt C. et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 2013; 8: e78538
6 Mir TA, Kherani S, Hafiz G. et al. Changes in retinal Nonperfusion associated with suppression of vascular Endothelial growth factor in retinal vein occlusion. Ophthalmology 2016; 123: 625-634
7 Clark WL, Boyer DS, Heier JS. et al. Intravitreal Aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 2016; 123: 330-336
8 Brown DM, Wykoff CC, Wong TP. et al. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina (Philadelphia, Pa) 2014; 34: 1728-1735
9 Thach AB, Yau L, Hoang C. et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 2014; 121: 1059-1066
10 Hattenbach LO, Feltgen N, Bertelmann T. et al. Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol (copenh) 2018; 96: e10-e18
11 Hoerauf H, Feltgen N, Weiss C. et al. Clinical efficacy and safety of Ranibizumab versus Dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 2016; 169: 258-267
12 Scott IU, VanVeldhuisen PC, Ip MS. et al. Effect of Bevacizumab vs. Aflibercept on visual acuity among patients with macular edema Due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 2017; 317: 2072-2087
13 Narayanan R, Panchal B, Das T. et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol 2015; 99: 954-959
14 Gado AS, Macky TA. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 2014; 42: 650-655
15 Lotfy A, Solaiman KAM, Abdelrahman A. et al. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina (Philadelphia, Pa) 2017;
16 Rajagopal R, Shah GK, Blinder KJ. et al. Bevacizumab versus Ranibizumab in the treatment of macular edema Due to retinal vein occlusion: 6-month results of the CRAVE study. Ophthalmic Surg Lasers Imaging Retina 2015; 46: 844-850
17 Bandello F, Augustin A, Tufail A. et al. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol 2018;
18 Yoon YH, Kim JW, Lee JY. et al. Dexamethasone Intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the Multicenter COBALT study. Ophthalmologica 2018; 240: 81-89 doi:10.1159/000487547
19 Goñi FJ, Stalmans I, Denis P. et al. Elevated Intraocular pressure after Intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther 2016; 5: 47-61
20 Parikh R, Ross JS, Sangaralingham LR. et al. Trends of anti-vascular Endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology 2017; 124: 352-358
21 Wang MD, Jeng-Miller KW, Feng HL. et al. Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves. Br J Ophthalmol 2016; 100: 1332-1336
22 Mishra SK, Gupta A, Patyal S. et al. Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous 2018; 4: 13 doi:10.1186/s40942-018-0114-2
23 Kube T, Sutter M, Trittler R. et al. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1385-1390
24 Bressler NM. Treatment of macular edema Due to central retinal vein occlusion: another score for repackaged Bevacizumab. JAMA 2017; 317: 2067-2069 doi:10.1001/jama.2017.5899
25 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049
26 Brown DM, Campochiaro PA, Bhisitkul RB. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602
27 Campochiaro PA, Wykoff CC, Singer M. et al. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 2014; 121: 2432-2442
28 Tadayoni R, Waldstein SM, Boscia F. et al. Individualized stabilization criteria-driven Ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 2016; 123: 1332-1344
29 Korobelnik JF, Holz FG, Roider J. et al. Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 2014; 121: 202-208
30 Brown DM, Heier JS, Clark WL. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013; 155: 429-437
31 Ziemssen F, Bertelmann T, Hufenbach U. et al. Delayed treatment initiation of more than 2 weeks: Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe 2016; 113: 143-151
32 Dirani A, Mantel I, Ambresin A. Recurrent macular edema in central retinal vein occlusion treated with Intravitreal Ranibizumab using a modified treat and extend regimen. Klin Monatsbl Augenheilkd 2015; 232: 538-541
33 Freund KB, Korobelnik JF, Devenyi R. et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina (Philadelphia, Pa) 2015; 35: 1489-1506
34 Hufendiek K, Pielen A, Framme C. Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: „Pro Re Nata versus Treat and Extend“. Klin Monatsbl Augenheilkd 2017; 235: 930-939 doi:10.1055/s-0042-122340
35 Larsen M, Waldstein SM, Boscia F. et al. Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 2016; 123: 1101-1111
36 Wai KM, Khan M, Srivastava S. et al. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice. Br J Ophthalmol 2017; 101: 574-579
37 Wecker T, Ehlken C, Bühler A. et al. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 2017; 101: 353-359
38 Eter N, Mohr A, Wachtlin J. et al. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 2017; 255: 77-87
39 Callizo J, Schmitz-Valckenberg S, Spital G. et al. Erläuterung des Behandlungserfolges bei RVV-Patienten mit VEGF Inhibition in einer prospektiven, nicht-interventionellen Studie über 12 Monate. DOG, Berlin (Retina: Intravitreale Injektionen). 2017
40 Feltgen N, Ziemssen F, Spital G. et al. Analysis of baseline factors affecting outcome of RVO patients to ranibizumab therapy in a prospective, non-interventional trial (OCEAN study). EURETINA, Barcelona (Vascular Diseases and Diabetc Retinopathy). 2017
41 Korobelnik JF, Kodjikian L, Delcourt C. et al. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 2016; 254: 2307-2318
42 Ip MS, Scott IU, VanVeldhuisen PC. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009; 127: 1101-1114 (Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5)
43 Tadayoni R, Waldstein SM, Boscia F. et al. Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 2017; 124: 1778-1787
44 Pielen A, Mirshahi A, Feltgen N. et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol (copenh) 2015; 93: e29-e37
45 Leitritz MA, Gelisken F, Ziemssen F. et al. Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol 2013; 97: 215-219
46 Lam FC, Chia SN, Lee RMH. Macular grid laser photocoagulation for branch retinal vein occlusion. Cochrane Database Syst Rev 2015; (11) CD8732
47 Donati S, Barosi P, Bianchi M. et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 2012; 22: 607-614
48 Russo V, Barone A, Conte E. et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Philadelphia, Pa) 2009; 29: 511-515
49 Tan MH, McAllister IL, Gillies ME. et al. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 2014; 157: 237-247
50 The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984; 98: 271-282 doi:10.1016/0002-9394(84)90316-7
51 Tomiyasu T, Hirano Y, Yoshida M. et al. Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Sci Rep 2016; 6: 29445 doi:10.1038/srep29445
52 Gozawa M, Takamura Y, Miyake S. et al. Photocoagulation of the retinal Nonperfusion area prevents the expression of the vascular Endothelial growth factor in an animal model. Invest Ophthalmol Vis Sci 2017; 58: 5946-5953
53 Campochiaro PA, Hafiz G, Mir TA. et al. Scatter Photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 2015; 122: 1426-1437
54 Wykoff CC, Ou WC, Wang R. et al. Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial. Ophthalmology 2017; 124: 919-921
55 Rehak M, Tilgner E, Franke A. et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 2014; 252: 745-752
56 Tomomatsu Y, Tomomatsu T, Takamura Y. et al. Comparative study of combined bevacizumab/targeted photocoagulation vs. bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol (Copenh) 2016; 94: e225-e230

Weiterführende Literatur
57 Heier JS, Campochiaro PA, Yau L. et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012; 119: 802-809
58 Campochiaro PA, Clark WL, Boyer DS. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 2015; 122: 538-544
59 Haller JA, Bandello F, Belfort R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
60 Haller JA, Bandello F, Belfort R. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2012; 117: 1134-1146
61 Brown DM, Campochiaro PA, Singh RP. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1124-1133
62 Kreutzer TC, Wolf A, Dirisamer M. et al. Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 2015; 233: 8-17
63 Heier JS, Clark WL, Boyer DS. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121: 1414-1420
64 Epstein DLJ, Algvere PV, von Wendt G. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012; 119: 1184-1189
65 Epstein DL, Algvere PV, von Wendt G. et al. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012; 119: 2587-2591
66 Kinge B, Stordahl PB, Forsaa V. et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010; 150: 310-314

Supplementary Material

Supporting Information

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss[*]

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss^[*]